Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

NCT ID: NCT00970944

Last Updated: 2012-09-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 184 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-02-28
• Study Completion Date: 2010-03-31

Brief Summary

This is a controlled trial of amantadine to improve level of function following severe traumatic brain injury.

The purpose of this study is:

1. To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves functional recovery from the vegetative and minimally conscious states

2. To determine whether amantadine-related gains in function persist following drug discontinuation

3. To determine the safety profile of amantadine in patients with disorders of consciousness

Detailed Description

Severe traumatic brain injury may result in severe disorders of consciousness (DOC), including coma, the vegetative state (VS) and the minimally conscious state (MCS). The longer the duration of impaired consciousness, the worse the ultimate functional prognosis, with only about half of those individuals who remain unconscious for a month post-TBI regaining consciousness within a year. The severe functional disability associated with prolonged DOC places enormous emotional, financial, ethical, and logistical strains on caregivers and major resource demands on society. Numerous treatments have been recommended to hasten the return of consciousness or improve the ultimate level of recovery, including various psychotropic drugs, "coma stimulation" therapy and others. However, none of these treatments has proven efficacy in well-controlled research. The main obstacles to Class I evidence in this area have been the small samples of individuals with serious DOC in individual facilities, the variability of recovery trajectories within this heterogeneous population, and the reluctance to undertake placebo controlled trials.

In the proposed study, 7 facilities (including two with TBI Model Systems designations) that participated in a multi-center research network called the Consciousness Consortium, join with four additional brain injury rehabilitation centers (two in the U.S. and two in Europe) and a Data Coordinating Center at Columbia University, to conduct a prospective double blind randomized controlled trial of amantadine hydrochloride. 184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) vs. placebo, followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure. We hypothesize superior recovery in the amantadine group and maintenance of that advantage after washout. We will also explore whether treatment response differs by time post-injury and by diagnosis (i.e., VS or MCS) at treatment onset, and whether specific outcomes of importance to caregivers are achieved more often in the amantadine group. We have developed plans for intensive education of caregivers and clinicians about this study to address perceived barriers to enrollment and will also use the information gathered during these interactions to develop consumer-oriented dissemination activities. Project outputs and findings will be disseminated to appropriate consumer and professional audiences using a variety of formats and will include: (1) improved family member understanding of DOC which will facilitate improved adjustment and caregiving and (2) clear guidance to clinicians regarding the effectiveness of amantadine for persons with DOC.

Conditions

Traumatic Brain Injury

Keywords

Traumatic Brain Injury; Rehabilitation; Disorders of Consciousness; Functional Outcome; Amantadine Hydrochloride

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Amantadine HCL

100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.

Group Type: EXPERIMENTAL

Amantadine Hydrochloride

Intervention Type: DRUG

184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo administered twice daily.

Interventions

Amantadine Hydrochloride

184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.

Intervention Type: DRUG

Placebo

Placebo administered twice daily.

Intervention Type: DRUG

Other Intervention Names

Symmetrel

Eligibility Criteria

Inclusion Criteria

• Individuals between ages 16 and 65 with traumatic brain injury as defined by the TBI Model System syllabus (i.e., damage to brain tissue caused by an external mechanical force as evidenced by loss of consciousness or post-traumatic amnesia due to brain trauma, skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical or mental status examination).
• Individuals are at least 4 weeks but less than 16 weeks post-injury and have a Disability Rating Scale (DRS) score at enrollment of 12 or greater, and no consistent command following or functional communication (as defined by the JFK.

Exclusion Criteria

• Women who are pregnant,
• Individuals with missile-type penetrating brain injury,
• Premorbid major CNS/developmental abnormality (e.g., mental retardation, prior significant brain damage, etc.),
• History of more than 1 seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) in the 4 weeks prior to enrollment (individuals with premorbid idiopathic epilepsy are eligible to enroll under two conditions: a) if their pre-injury seizure frequency was less than once/month and they have had no more than 1 seizure/month since injury and b) if a clear provocation was present that would otherwise disqualify a subject, the subject can be enrolled, since these events would not be considered idiopathic),
• Prior exposure to AH post-TBI,
• Unwillingness to discontinue or change confounding psychotropic drugs prior to enrollment, OR
• Allergy or medical contraindication to AH and significant impairment of renal function (as evidenced by a calculated creatinine clearance of < 60 ml/min).

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

U.S. Department of Education

FED

Sponsor Role: collaborator

JFK Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Joseph T Giacino

Director of Rehabilitation Neuropsychology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Joseph T. Giacino, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Spaulding Rehabilitation Hospital

John Whyte, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Moss Rehabilitation Research Institute

Locations

Braintree Rehabilitation Hospital

Braintree, Massachusetts, United States

Methodist Rehabilitation Center

Jackson, Mississippi, United States

Columbia University

New York, New York, United States

Sunnyview Rehabilitation Hospital

Schenectady, New York, United States

Charlotte Rehabilitation Center

Charlotte, North Carolina, United States

Moss Rehabilitation Research Institute

Elkins Park, Pennsylvania, United States

Bryn Mawr Rehabilitation Hospital

Malvern, Pennsylvania, United States

Texas NeuroRehabilitation Center

Austin, Texas, United States

Hvidovre University Hospital

Hvidovre, , Denmark

Neurologische Klinik Bad Aibling

Bad Aibling, , Germany

Fachkrankenhaus Neresheim

Neresheim, , Germany

Countries

United States; Denmark; Germany

References

Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012 Mar 1;366(9):819-26. doi: 10.1056/NEJMoa1102609.

Reference Type: DERIVED

PMID: 22375973 (View on PubMed)

Other Identifiers

H133A031713

Identifier Type: -

Identifier Source: org_study_id